Cervical cancer awareness and vaccine hesitancy with respect to HPV vaccination in urban community of Faridabad, Haryana, India Authors: Abhishek Jaiswal, Pooja Goyal, Sneha Kumari, Dhairya Aggarwal Published: 2026 ABSTRACT PurposeTo assess cervical cancer awareness and willingness to receive HPV vaccination among females aged 9–45 years in an urban community of Faridabad, Haryana, India.Materials and MethodsA community-based cross-sectional study was conducted among 302 female residents of Prem Nagar, Faridabad. Participants were assessed for their knowledge about cervical cancer and their willingness for HPV vaccination, screened for cervical cancer–related symptoms, and those symptomatic were referred for appropriate diagnostic evaluation. Descriptive statistics were calculated, and associations between variables were tested using chi-square tests.ResultsThe mean age of participants was 27.14 (standard deviation, 8.32) years; most were married 239 (79.1%). Awareness of cervical cancer was low, with only 73 (24.2%) having heard of the disease and very limited knowledge of its etiology and prevention. Awareness of HPV vaccination was extremely poor 32 (10.6%). Despite this, 219 (72.5%) expressed willingness to receive the vaccine. The main barriers among those unwilling 83 (27.5%) were lack of interest or motivation 44 (53.0%) and limited decision-making autonomy 25 (30.1%), while fear and knowledge deficits were less common.ConclusionAwareness regarding cervical cancer and HPV vaccination was markedly inadequate in this urban community; however, willingness to accept vaccination was high. Further rollout of vaccination by government, targeted health education, community engagement, and empowerment of women in health decision-making could substantially improve vaccine uptake and prevent cervical cancer. INTRODUCTION Cervical cancer starts in the cells lining the cervix—the lower part of the uterus (womb). The cervix connects the body of the uterus (the upper part where a fetus grows) to the vagina (birth canal). Cancer starts when cells in the body begin to grow out of control [1]. Worldwide, cervical cancer is the fourth most frequent cancer in women with an estimated 604,000 new cases in 2020 [23]. Of the estimated 342,000 deaths from cervical cancer in 2020, about 90% of these occur in low- and middle-income countries [23]. Women living with human immunodeficiency virus (HIV) are 6 times more likely to develop cervical cancer compared to women without HIV, and an estimated 5% of all cervical cancer cases are attributable to HIV [4]. Moreover, in all world regions the contribution of HIV to cervical cancer falls disproportionately on younger women. The highest estimated incidence rates for cervical cancer are in sub-Saharan Africa, Melanesia, Latin America and the Caribbean, South-Central Asia and South-East Asia [2]. Cervical cancer is a preventable disease as it has a well-defined, long pre-malignant phase which can be detected by regular screening tests and follow up. Unfortunately, most women in India are not aware about the screening [2]. Nearly all cases of cervical cancer can be attributable to human papillomavirus (HPV) infection. HPV is a group of viruses and one of the causative agents in the sexually transmitted infections in men and women with and without clinical lesions. HPV types (16 and 18) cause 70% of cervical cancers and precancerous cervical lesions worldwide [5]. There are currently 4 vaccines that have been prequalified by World Health Organization, all protecting against HPV types 16 and 18, which are known to cause at least 70% of cervical cancers. The 9-valent vaccine protects against 5 additional oncogenic HPV types, which cause a further 20% of cervical cancers. Two of the vaccines also protect against HPV types 6 and 11, which cause anogenital warts. Clinical trials and post-marketing surveillance have shown that HPV vaccines are safe and effective in preventing infections with HPV infections, high grade precancerous lesions and invasive cancer [6]. India has a population of 511.4 million women ages 15 years and older who are at risk of developing cervical cancer according to ICO/IARC Human Papillomavirus and Related Cancers Fact Sheet (2023) [7]. Current estimates indicate that in 2022 in India, 127,526 women were diagnosed with cervical cancer and 79,906 died from the disease. Cervical cancer ranks as the 2nd most frequent cancer among women in India and the 2nd most frequent cancer among women between 15 and 44 years of age [8]. About 5.0% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 83.2% of invasive cervical cancers are attributed to HPVs 16 or 18 [5]. Based on Indian studies about 82.7% of invasive cervical cancers showed the presence of HPVs 16 or 18 (systematic reviews and meta-analyses of the literatures by ICO HPV Information Centre). According to research, HPV types 16 and 18 are found in around 83.2% of instances of invasive cervical cancer in India, indicating that they are the main causes of the illness [7]. The great majority of instances of cervical cancer are caused by these high-risk HPV strains, with HPV 16 alone frequently detected in 70%–90% of cases [7]. Other epidemiological risk factors for cervical cancer are early age at marriage, multiple sexual partners, multiple pregnancies, poor genital hygiene, malnutrition, use of oral contraceptives, and lack of awareness [9]. India also has the highest (age standardized) incidence rate as 17.7 (per 100,000 women per year) of cervical cancer and is one of the highest in South Asia (estimations for 2022) [8], Cervical cancer can be prevented by vaccinating all young females against the HPVs and by screening and treating precancerous lesions in women. In addition, if cervical cancer is detected early and treated in earlier stages it can be cured [10]. To strengthen this fight against Cervical cancer, Government of India launched a free nationwide HPV vaccination drive for 1.15 crore girls aged 14 years [11]. The Global strategy towards eliminating cervical cancer as a public health problem, adopted by the World Health Assembly in 2020, recommends a comprehensive approach to cervical cancer prevention and control. The recommended actions include interventions across the life course (Table 1) [2]. Table 1Preventive methods adapted from World Health OrganizationStagePrimary preventionSecondary preventionTertiary preventionTarget populationGirls 9–14 years (boys also if possible)Women ≥30 years (≥25 years if HIV positive)All women as neededKey interventionsHPV vaccinationHPV screening testTreatment of cancer• Health education• Early treatment if test positive• Surgery• Tobacco warning• Radiotherapy• Sex education• Chemotherapy• Condom promotion• Palliative care• Male circumcisionHIV, human immunodeficiency virus. Preventive methods adapted from World Health Organization HIV, human immunodeficiency virus. MATERIALS AND METHODS Study design, setting, and population A community-based cross-sectional study was conducted to assess the awareness of and willingness to receive the HPV vaccine among females aged 9–45 years. The study was carried out in Prem Nagar, a field practice area of the Urban Health Training Centre (UHTC) affiliated with ESIC Medical College and Hospital, Faridabad, located in Faridabad. Eligible participants included female residents of Prem Nagar within the specified age group. Written informed consent or assent was obtained from all participants prior to enrollment. For participants younger than 18 years, additional consent was obtained from a parent or legal guardian. Sample size The sample size for the present cross-sectional study was calculated using the formula n=4pq/L2, where p represents the prevalence, q=100 − p, and L is the absolute allowable error. Based on a previously reported prevalence of 68.3% of willingness regarding HPV vaccination and assuming an absolute precision of 5%, the calculated sample size was 346. So, 346 females were selected using simple random sampling [12], out of which 302 gave consent to take part in the study (Fig. 1). Flowchart depicting recruitment of participants. SRS, simple random sampling. Data collection A pretested semi-structured questionnaire was used as the interview schedule for data collection. The tool was prepared in Hindi to ensure easy comprehension, as Hindi is the primary language of communication among the residents. Pretesting of the questionnaire was conducted among outpatient attendees at the UHTC, Prem Nagar. Difficulties encountered during pretesting were addressed, and questions that were hard to understand were modified for clarity and simplicity. Data collection was carried out through house-to-house visits in the community. Information was obtained from eligible female residents (aged 9–45 years) using the semi-structured interview schedule, which included sections on sociodemographic characteristics, awareness of cervical cancer, symptoms for early-stage cancer, knowledge and perceptions regarding HPV vaccination, and factors related to vaccine hesitancy. Residents who were insured under ESI and were willing for HPV vaccination were motivated to get HPV vaccination free of cost UHTC, Prem Nagar under a campaign mode. Participants reporting symptoms suggestive of cervical pathology that included intermenstrual or postcoital bleeding, postmenopausal bleeding, abnormal or foul-smelling vaginal discharge, persistent pelvic, back or leg pain, significant weight loss, fatigue, loss of appetite, and swelling of one or both lower limbs were counselled and advised to seek further clinical evaluation at appropriate healthcare facilities, including ESIC Hospital or B.K. Hospital, as applicable. This referral process was undertaken as part of routine ethical clinical care and was not included as a formal study outcome. Analysis Data collected was entered in Microsoft excel, and checked for any mistakes. Data was cleaned and analyzed using STATA 17 (Stata Statistical Software: Release 17; StataCorp LLC, College Station, TX, USA). Categorical data was presented as frequency and percentage. The χ2/Fisher exact test was applied to see the association between the categorical variables. Ethics Informed written consent was taken from the participants after informing them the objectives and procedure of the study in local language (Hindi). Ethical approval was taken from the Institute Ethics Committee, ESIC MCH, Faridabad vide letter No. EC File No: 134 X/11/13/2022- IEC/111. RESULTS A total of 302 participants were included in the analysis. The mean age was 27.14 years (standard deviation [SD], 8.32), with the largest proportion aged 26–45 years (48.7%), followed by 19–26 years (33.4%), 15–19 years (13.2%), and 9–14 years (4.6%). Most participants were married (79.1%). The mean height and weight were 151.24 cm (SD, 7.12) and 51.29 kg (SD, 9.30), respectively. The mean age at menarche was 13.15 years (SD, 1.40), and the mean age at marriage was 18.92 years (SD, 3.21). Comorbid conditions were infrequent; thyroid disorders (3.3%) and hypertension (3.0%) were the most commonly reported, followed by diabetes mellitus (0.7%) and asthma (0.3%). A family history of cancer was reported by 4.6% of participants (Table 2). Table 2Demographic and clinical characteristics of study participantsCharacteristicValues (n=302)Age (yr)27.14±8.329–1414 (4.6)15–1940 (13.2)20–26101 (33.4)27–45147 (48.7)Anthropometric measuresHeight (cm)151.24±7.12Weight (kg)51.29±9.30Marital statusMarried239 (79.1)Single/unmarried63 (20.9)Age at marriage (yr)18.92±3.21Age at menarche (yr)13.15±1.40ComorbiditiesThyroid disorder10 (3.3)Hypertension9 (3.0)Diabetes mellitus2 (0.7)Asthma1 (0.3)Family history of cancer14 (4.6)Values are presented as mean ± standard deviation or number (%). Demographic and clinical characteristics of study participants Values are presented as mean ± standard deviation or number (%). Gynaecological symptoms were reported by a subset of participants. Fatigue was the most common symptom (28.8%), followed by foul-smelling vaginal discharge (15.9%), pelvic pain (14.9%), and significant weight loss of at least 10% within 3 months (6.0%). Intermenstrual bleeding was rare (1.0%) (Table 3). Table 3Gynaecological symptoms in study participantsSymptomValuesPelvic pain45 (14.9)Fatigue87 (28.8)Significant weight loss (≥10% in 3 mon)18 (6.0)Foul-smelling vaginal discharge48 (15.9)Intermenstrual bleeding3 (1.0)Values are presented as number (%). Gynaecological symptoms in study participants Values are presented as number (%). Awareness of cervical cancer was low. Only 73 participants (24.2%) reported having heard about cervical cancer. Among those aware, knowledge of etiology was poor, with 94.5% reporting that they did not know the cause. Very few participants attributed cervical cancer to bacterial (4.1%) or viral causes (1.4%). Awareness that cervical cancer is preventable was reported by 30.1% of those who had heard about the disease. Among participants aware of prevention, commonly mentioned methods included genital hygiene (40.9%), monogamous relationships (9.1%), and appropriate treatment of infections (9.1%), while 40.9% were unable to specify any preventive method (Table 4). Table 4Awareness and knowledge about cervical cancerKnowledge domainValuesHeard about cervical cancer (n=302)Yes73 (24.2)No229 (75.8)Knowledge about cervical cancer aetiology (n=73)Does not know69 (94.5)Bacteria3 (4.1)Virus1 (1.4)Knowledge about prevention (n=73)Aware that cervical cancer can be prevented22 (30.1)Not aware of prevention51 (69.9)Prevention methods mentioned (n=22)Does not know9 (40.9)Good hygiene of genital organs9 (40.9)Monogamous relationship2 (9.1)Proper treatment of infections2 (9.1)Values are presented as number (%). Awareness and knowledge about cervical cancer Values are presented as number (%). Awareness of the HPV vaccine was very limited. Only 32 participants (10.6%) had heard about the vaccine, whereas 270 (89.4%) were unaware of its existence (Table 5). Table 5HPV vaccine awarenessHeard about HPV vaccineValuesYes32 (10.6)No270 (89.4)Values are presented as number (%).HPV, human papillomavirus. HPV vaccine awareness Values are presented as number (%). HPV, human papillomavirus. Despite low awareness, most participants expressed willingness to receive HPV vaccination. Overall, 219 participants (72.5%) indicated willingness, while 83 (27.5%) were unwilling. Among those unwilling, the most frequently reported barrier was lack of interest or motivation (53.0%), followed by issues related to decision-making autonomy (30.1%). Fear and hesitancy (6.0%), knowledge deficits (2.4%), and other barriers (8.4%) were less commonly reported (Tables 6 and 7). Table 6Willingness to accept HPV vaccination and barriersCharacteristicValuesWillingness to receive HPV vaccine (n=302)Willing219 (72.5)Not willing83 (27.5)Barriers (n=83)Decision-making autonomy issues25 (30.1)Lack of interest/motivation44 (53.0)Fear and hesitancy5 (6.0)Knowledge deficit2 (2.4)Other barriers7 (8.4)Values are presented as number (%).HPV, human papillomavirus. Willingness to accept HPV vaccination and barriers Values are presented as number (%). HPV, human papillomavirus. Table 7Association of socio-demographic and awareness variables with willingness to receive HPV vaccinationVariableCategoryWillingNot willingTotalp-valueAge group (yr)20–2666 (65.3)35 (34.7)101 (100.0)0.25915–1931 (77.5)9 (22.5)40 (100.0)27–45111 (75.5)36 (24.5)147 (100.0)9–1411 (78.6)3 (21.4)14 (100.0)BMI (kg/m2)<18.522 (66.7)11 (33.3)33 (100.0)0.13118.5–24.9158 (76.0)50 (24.0)208 (100.0)>2539 (63.9)22 (36.1)61 (100.0)Marital statusMarried172 (72.0)67 (28.0)239 (100.0)0.796Single/unmarried47 (74.6)16 (25.4)63 (100.0)Any co morbidityYes15 (68.2)7 (31.8)22 (100.0)0.822No204 (72.9)76 (27.1)280 (100.0)Family history of cancerYes11 (78.6)3 (21.4)14 (100.0)0.831No208 (72.2)80 (27.8)288 (100.0)Heard of cervical cancerYes58 (79.5)15 (20.5)73 (100.0)0.170No161 (70.3)68 (29.7)229 (100.0)Knows cervical cancer is preventableYes19 (86.4)3 (13.6)22 (100.0)0.529No39 (76.5)12 (23.5)51 (100.0)Heard of HPV vaccineYes25 (78.1)7 (21.9)32 (100.0)0.588No194 (71.9)76 (28.1)270 (100.0)Values are presented as number (%).HPV, human papillomavirus; BMI, body mass index. Association of socio-demographic and awareness variables with willingness to receive HPV vaccination Values are presented as number (%). HPV, human papillomavirus; BMI, body mass index. A higher proportion of participants across most age groups expressed willingness to receive vaccination, with the highest willingness observed among 9–14 years (78.6%) and 15–19 years (77.5%) age groups. Participants with normal body mass index (18.5–24.9) showed relatively higher willingness (76.0%) compared to underweight and overweight groups. Married (72.0%) and unmarried (74.6%) participants demonstrated comparable acceptance levels. Participants who had heard of cervical cancer (79.5%), were aware that cervical cancer is preventable (86.4%), or had heard of the HPV vaccine (78.1%) showed relatively higher willingness compared to their counterparts. However, none of the associations were statistically significant (p>0.05), indicating that willingness to receive HPV vaccination was not significantly influenced by socio-demographic characteristics, comorbidities, family history of cancer, or awareness-related variables in the present study. Although associations between awareness-related variables and willingness to receive HPV vaccination did not reach statistical significance, higher acceptance was observed among participants who had prior awareness of cervical cancer, its preventability, and HPV vaccination. These trends may indicate a meaningful relationship; however, the relatively small subgroup sizes may have reduced statistical power, increasing the possibility of a type II error. Among the 219 participants who were willing to get HPV vaccine, 111 were ESIC beneficiaries, of these participants, a total of 99 participants received the first dose of the HPV vaccine, of whom 89 proceeded to receive the second dose and 70 got 3 doses. Among the 111 ESIC beneficiaries who initially expressed willingness to receive HPV vaccination, 12 did not receive the first dose because of personal barriers, including inability to attend the vaccination session and family-related constraints, indicating that expressed willingness may not necessarily translate into actual uptake. Among those who completed the full vaccination schedule (total 70), 60 participants belonged to the 15–45 years age group, while 10 were in the 9–14 years age group. Overall, 29 participants were partially immunised; among them, 19 individuals (all aged 15–45 years) received 2 doses. Additionally, 10 participants received only a single dose, including 9 in the 15–45 years age group and 1 in the 9–14 years age group. DISCUSSION The current study focused on awareness and willingness regarding HPV vaccine against Cervical cancer among females of the age group 9–45 years in a community. The mean age of the 302 individuals in the study was 27.14 years (SD, 8.32), with the majority (79.1%) being married and nearly half being between the ages of 26 and 45. The average weight and height were 51.29 kg (SD, 9.30) and 151.24 cm (SD, 7.12), respectively. The average age at marriage and menarche was 18.92 years (SD, 3.21) and 13.15 years (SD, 1.40), respectively. Self-reported comorbidities were hypertension (3.0%) and thyroid problems (3.3%). 4.6% of individuals had a family history of cancer. Whereas a study enrolled 114 nursing students to check for awareness regarding cervical cancer, 60.5% were aged between 21 and 25 years old. Most of the students were single (95.6%) [13]. Contrary to substantial burden of cervical cancer in India, there was observed extremely low levels of awareness and etiological knowledge in this population. Fewer than 1 in 4 participants (24.2%) had ever heard of cervical cancer, and almost all those who were aware could not identify any cause, in sharp contrast to a study conducted in Delhi, India where a majority (85.1%) had at least heard of cervical cancer or recognised HPV as a key risk factor [14]. The proportion aware of prevention was quite less, i.e., 30% of the population who had heard about cervical cancer, and prevention was predominantly understood in terms of general genital hygiene rather than evidence-based measures such as HPV vaccination. These findings point to persistent and profound informational gaps among women about cervical cancer. Similarly in a study done on 240 girls in India (65%) of the study population knew that prevention of cervical cancer is possible [15]. These results are contrary to a study in Nigeria where according to the majority of women (95.7%), cervical cancer can be prevented. A vast majority (96.2%) concurred that cervical cancer can be avoided by leading a healthy lifestyle and being aware of risk factors [16]. In the study participants awareness of HPV vaccination was particularly poor, with only around one in ten participants (10.6%) reporting any knowledge of the vaccine, markedly lower than levels reported in a study of 250 participants where awareness about HPV vaccination was significantly lower in slum areas (22.5%) compared to non-slum areas (48.8%) in district of Nellore [17]. Nonetheless, willingness to accept HPV vaccination, once the benefits of the vaccine were explained was high: nearly 3-quarters (72.5%) of women expressed readiness to be vaccinated, a level comparable to willingness among school going adolescent girls of Ethopia that was found to be 56% CI (52.1–59.9) [18]. It was also seen in our study participants that those who were aware of HPV vaccination had higher willingness for the vaccine. However, it was not significantly associated. A total of 99 participants received the first dose of the HPV vaccine, of whom 89 proceeded to receive the second dose and 70 completed all 3 doses. Barriers among women unwilling to receive HPV vaccination provides great insights. Lack of interest or motivation emerged as the most frequent barrier, followed by constraints in decision-making autonomy, whereas explicit fear, vaccine hesitancy, or stated knowledge deficits were less frequently reported. A study reported that many participants expressed fear of adverse effects of vaccination, including immediate side effects and long-term health issues [19]. A scoping review conducted in India found that lack of awareness, sociocultural stigma, economic constraints, and insufficient assistance from the health system were highlighted as some of the main barriers to receive HPV vaccination. Government awareness initiatives, healthcare provider recommendations, and school-based interventions were found to facilitate HPV vaccination [20]. The findings indicate a generally high willingness to receive the HPV vaccine, particularly among participants with greater awareness of cervical cancer and its prevention, although these associations were not statistically significant. In this context, the recent pilot implementation of HPV vaccination by the Government represents a timely and commendable step toward strengthening cervical cancer prevention efforts [11]. Such initiatives have the potential to improve awareness, acceptability, and uptake of the vaccine taking a leap towards eliminating cervical cancer. This study highlights a critical gap between the high burden of cervical cancer and the low level of awareness regarding the disease and its prevention among women in an urban community of Faridabad. Knowledge of HPV vaccination was particularly limited; nevertheless, a substantial proportion of participants were willing to be vaccinated when informed, indicating strong potential for improving coverage through education and outreach. Barriers such as lack of motivation and restricted decision-making autonomy emphasize on the influence of sociocultural factors on preventive health behaviour. Strengthening community-based awareness programs, integrating HPV education into existing health services, promoting school-based vaccination initiatives, and enhancing women’s autonomy in health decisions are essential to accelerate cervical cancer prevention efforts. Given the encouraging levels of willingness observed in the present study, expansion of the ongoing pilot HPV vaccination programme into a wider, phased rollout should be considered. Scaling up vaccination services, along with targeted awareness campaigns, could substantially contribute to reducing the burden of cervical cancer in the long term and elimination as a public health problem.